Occam Global is the executive search firm and leadership advisory partner for entrepreneurs, investors, and corporations pursuing exceptional goals in frontier technologies, including life sciences, defense, robotics, and venture capital, worldwide.
Since 2012, Occam has partnered with leading founders, CEOs, and investors across life sciences and deep tech to deliver high-performing C-suite and board leadership. From stealth startups to public markets, we run retained executive search, advise on organizational strategy, and invest alongside visionary teams building category-defining companies.
Our edge: an unmatched ability to attract exceptional business and scientific leaders, seamless access to rare talent, and a relentless commitment to results — guided by high ethics and enlightened aggression.
Whether you’re launching, leading, or investing, Occam fuels growth through the power of talent. Visit occam-global.com to learn more.
Occam was founded in 2012 on a simple yet uncommon belief: executive search could be more creative, thoughtful, and principled than the industry norm.
After a 25-year career shaping leadership at Fidelity Investments, William ”Bill” Holodnak partnered with his son, John, to build a firm defined by focus, judgment, and ethics.
From the beginning, we chose to partner closely with founders and entrepreneurial leaders as they navigate moments that define their companies. We understood that early-stage and high-growth businesses require more than resume shuffling — they require judgment calls made under incomplete information, the kind no algorithm can make for you. Today, Occam is a global executive search firm trusted by founders, boards, and investors in high-stakes leadership moments.
That judgment is built from pattern recognition — hundreds of these decisions, across every stage from founding team to post-IPO board — brought to bear on the search in front of us. It’s why investors bring us in before the problem is even fully defined, and why the leaders we place deliver proven track records, real impact, and long-term value.
We built our firm on the pillars of objectivity, undiluted ethics, and enlightened aggression.
With a process that’s rooted in relationships, data, and intellect, we’ve provided professional judgments that have made a lasting impact on our partners.
Our judgements are simultaneously inspired by instinct and pragmatism, resulting in balanced outcomes designed to endure.
New York City-based executive search firm Occam Global has recruited Chris Boulton as the new CEO of Prolynx. “We engineered this platform to enable medicines that were previously impossible to make,” said Daniel Santi, co-founder of Prolynx. “Having established the viability and versatility of our technology in earlier clinical applications, we have now optimized it to specifically address
New York City-based executive search firm Occam Global has assisted in the recruitment of Troy Lionberger as chief business officer of biotechnology company A-Alpha Bio. “Troy brings a rare blend of deep technical fluency and commercial creativity,” said David Younger, co-founder and CEO of A-Alpha Bio. “His track record speaks for itself—from inventing platform applications to
New York City-based recruitment firm Occam Global has placed Emile Nuwaysir as president, chief executive officer and member of the board of directors of gene therapy company Ensoma. In conjunction with the CEO appointment, Ensoma executive chairman Paula Soteropoulos will transition to the role of chairman of the board, and Kush M. Parmar, managing partner
In May 2026, Occam Global placed Natalie Holles as CEO of Aura Biosciences (NASDAQ: AURA). Natalie is a proven biopharma CEO with a track record of building and leading innovative companies through critical inflection points. Most recently, she served as President and CEO of Third Harmonic Bio, where she guided the company through its IPO and advanced its clinical pipeline. Prior to
In March 2026, Occam placed Athena Countouriotis, MD, on the Board of Directors of Umoja Biopharma and Andrew C. Chan, MD, PhD, on Umoja’s Scientific Advisory Board. Countouriotis is Co-Founder, President, and CEO of Avenzo Therapeutics and previously led Turning Point Therapeutics through its IPO and $4.1 billion acquisition by Bristol Myers Squibb in 2022. Her career spanssenior R&D and executive roles
In March 2026, Occam Global, a leader in executive recruiting for TechBio, appointed Marcus Schindler, PhD, to Cradle’s Advisory Board. Cradle is an AI-powered protein engineering company accelerating innovation across the life sciences. Schindler most recently served as Executive Vice President and Chief Scientific Officer at Novo Nordisk, where he led global research and early development across major therapeutic
NEW YORK, Jan. 21, 2026 — Occam Global, a leading executive search and advisory firm to life science innovators, announced today the successful placement of Craig T. Basson, MD, PhD, as CMO and President of R&D at Variant Bio, a genomics-driven AI drug discovery company. Basson brings more than 25 years of leadership experience across academic medicine, global pharmaceutical development,
Case Studies
Read about how Occam Global is helping innovative organizations tackle their biggest executive recruitment challenges
Blog & Insights
Discover new tips, industry news and guides by Occam Global
-Latest Interview: Whit Bernard, CEO of Metsera